PIK3CB and cancer: As an orally bioavailable pan-PI3K inhibitor, PX-866 has entered into clinical trials for many cancers including ovarian, colorectal, prostate, head and neck (H&N) cancers, melanoma, NSCLC and GBM [57–62].